Loading...
XSTO
ACARIX
Market cap35mUSD
Dec 04, Last price  
0.30SEK
1D
-1.62%
1Q
1.33%
Jan 2017
-98.05%
IPO
-97.22%
Name

Acarix AB

Chart & Performance

D1W1MN
XSTO:ACARIX chart
P/E
—
P/S
54.38
EPS
—
Div Yield, %
—
Shrs. gr., 5y
89.32%
Rev. gr., 5y
27.28%
Revenues
6m
-0.62%
000638,0001,024,0001,857,0002,170,0003,760,0005,822,0006,241,0006,202,000
Net income
-66m
L-14.97%
-19,209,000-12,393,000-48,240,000-29,776,000-42,271,000-46,459,000-41,548,000-51,802,000-77,495,000-77,839,000-66,187,000
CFO
-63m
L-22.17%
-20,871,000-8,631,000-9,056,000-40,539,000-38,609,000-44,533,000-36,686,000-48,007,000-74,869,000-81,366,000-63,325,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases in Germany, Sweden, the Middle East, Switzerland, Austria, and internationally. The company offers CADScor System, a non-invasive and ultra-sensitive analytical device for the diagnosis of coronary artery disease. Acarix AB (publ) was founded in 2009 and is headquartered in Malmö, Sweden.
URL
https://acarix.com/
IPO date
Dec 19, 2016
Employees
20
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT